When do you consider local therapies (i.e. TACE) in patients with intrahepatic cholangiocarcinoma who do not tolerate or respond to chemothearpy or who are not surgical candidates?

Topics: Gastrointestinal Cancers • Medical Oncology

Answer from: Medical Oncologist at Community Practice

In the same way that patients with hepatocellular carcinoma can benefit from liver directed therapies, patients with intrahepatic cholangiocarcinoma who have no evidence of extrahepatic disease may also be good candidates for these therapies, which can provide local control with fewer toxicities. Lo...

Comments

Medical Oncologist at UCSF Medical Center
In addition to @Autumn J. McRee's comments above, ...

Answer from: Radiation Oncologist at Community Practice

The treatment of choice would be EBRT, ideally delivered to ablative doses or at least over 80 BED (Tao et al., PMID 26503201).For LC and OS benefits. This is an NCCN based recommendation based off of retrospective and single arm prospective (Hong et al., PMID 26668346) data. Two year LC 94% of...

Related Questions